Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic peripheral blood progenitor cells
- Development stage
- Phase 2
- Lead developer
- Case Comprehensive Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic peripheral blood progenitor cells (PBPC) are hematopoietic stem cells collected from the peripheral blood of a histocompatible donor, typically a sibling, following mobilization with growth factors such as filgrastim. In the context of the Case Comprehensive Cancer Center clinical trial (NCT00014534), these cells are used as a therapeutic transplant following a high-dose conditioning regimen consisting of busulfan and cyclophosphamide. The primary objective of this cell therapy is to reconstitute the recipient's hematopoietic and immune systems after myeloablative chemotherapy has eliminated diseased bone marrow. Additionally, the donor-derived immune cells can provide a graft-versus-tumor (GVT) effect, where they recognize and eliminate residual malignant cells in patients with hematologic malignancies such as leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome.
- Other names
- allogeneic peripheral blood stem cellsPBPCallogeneic PBSCperipheral blood progenitor cell transplantation
Beyond the preview
Go deeper on allogeneic peripheral blood progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic peripheral blood progenitor cells.